Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

(OP:MAJI)

0.0600 UNCHANGED
Streaming Delayed Price Updated: 3:47 PM EST, Dec 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

All News about MAJI

News headline image
Exousia Pro, Inc. Announces Executed LOI for Strategic Acquisition of High-Revenue Telehealth Platform to Accelerate Nutraceutical Commercialization
Via ACCESS Newswire
News headline image
Exousia Pro, Inc. Revolutionizes Nutraceuticals With Launch Of Maxasome(TM): The First All-Natural, Biologically Active Exosomal Supplement
Via ACCESS Newswire
News headline image
Exousia Pro, Inc. Completes Exclusive Licensing Agreement With the University of Central Florida for Novel Cancer Diagnostic and Therapy Platforms
Via ACCESS Newswire
News headline image
Exousia Pro Initiates Strategic Realignment, Acquires Controlling Stake in SEC-Reporter Lamy (LMMY) in All-stock Exchange Transaction for Exousia AI, to Advance Growth and Enhance Shareholder Value
Via ACCESS Newswire
News headline image
Exousia Pro Creates New Subdivisions
Via ACCESS Newswire
News headline image
Exousia Pro Announces Breakthrough In Exosome-Based Delivery
Via ACCESS Newswire
News headline image
Exousia Pro is Excited to Announce that it has Received Orphan Drug Designation from the FDA
Via ACCESS Newswire
News headline image
Exousia Pro Announces Groundbreaking Study to Revolutionize the Global Edibles Market with CBD-Loaded Exosomes
Via ACCESS Newswire
News headline image
Exousia Pro Reports Positive Outcome in Legal Proceeding
Via ACCESS Newswire
News headline image
Exousia Pro Files Provisional Patent for Novel Extracellular Vesicle Loading Method, Tapping into Multi-Billion Dollar Markets
Via ACCESS Newswire
News headline image
Exousia Pro Announces Strategic Acquisition to Launch a New Telehealth Division
Via ACCESS Newswire
News headline image
Exousia Pro Files Reg A.
Via ACCESS Newswire
News headline image
Exousia Pro Expands its Scientific Advisory Board
Via ACCESS Newswire
News headline image
Exousia Pro Will Launch a Web Series with Our New Consultant
Via ACCESS Newswire
News headline image
Exousia Pro Finishes Preclinical Trial for Glioblastoma Ahead of Schedule - Bolstering Orphan Drug Application
Via ACCESS Newswire
News headline image
Exousia Pro CSO Revealed Significant Findings About the Glioblastoma Study in a Spaces Interview
Via ACCESS Newswire
News headline image
Exousia Pro Offers Guidance on New Subdivisions
Via ACCESS Newswire
News headline image
Exousia Pro to Deliver 500 Billion Dried Exosomes for Trade Show
Via ACCESS Newswire
News headline image
Exousia Pro Issues Update on Name Change
Via ACCESS Newswire
News headline image
Exousia Pro Has Appointed Matthew Dwyer As Its New President
Via ACCESS Newswire
News headline image
Exousia Pro Issues and Update on its FDA Orphan Drug Status
Via ACCESS Newswire
News headline image
Exousia Pro Officially Announces the Production of Plant-Based Exosomes Has Begun
Via ACCESS Newswire
News headline image
Exousia Has Successfully Renegotiated Its License Agreement
Via ACCESS Newswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.